Compare KB & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KB | EW |
|---|---|---|
| Founded | 2008 | 1958 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.2B | 48.9B |
| IPO Year | 2008 | 1999 |
| Metric | KB | EW |
|---|---|---|
| Price | $120.93 | $92.07 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 21 |
| Target Price | N/A | ★ $96.37 |
| AVG Volume (30 Days) | 253.9K | ★ 5.0M |
| Earning Date | 04-23-2026 | 04-23-2026 |
| Dividend Yield | ★ 2.31% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.07 |
| Revenue | N/A | ★ $6,067,600,000.00 |
| Revenue This Year | $18.22 | $13.39 |
| Revenue Next Year | $3.21 | $9.81 |
| P/E Ratio | ★ $9.90 | $83.85 |
| Revenue Growth | N/A | ★ 11.55 |
| 52 Week Low | $76.31 | $72.30 |
| 52 Week High | $125.66 | $96.29 |
| Indicator | KB | EW |
|---|---|---|
| Relative Strength Index (RSI) | 55.51 | 64.12 |
| Support Level | $113.10 | $81.88 |
| Resistance Level | $125.62 | $96.29 |
| Average True Range (ATR) | 2.40 | 2.54 |
| MACD | -0.04 | 0.69 |
| Stochastic Oscillator | 66.59 | 93.61 |
KB Financial Group Inc. is a financial holding company in Korea. The company operations include Kookmin Bank, one of the commercial banks in Korea. The company's subsidiaries collectively engage in a broad range of businesses, including commercial banking, credit cards, asset management, non-life and life insurance, capital markets activities, and international banking and finance. The company's segments include the Banking business, Securities business, Non-life Insurance business, Credit card business, and Life Insurance business. The Group generates the majority of its revenue from the Banking business.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.